Skip to main content
SpringerLink
Log in

Onkologika

  • Chapter
Arzneiverordnungs- Report 2014

Zusammenfassung

Das höchste Verordnungsvolumen der Onkologika haben Hormonantagonisten zur Behandlung des Mammakarzinoms und des Prostatakarzinoms, auf die fast 70% der definierten Tagesdosen (DDD) entfallen. Alle anderen onkologischen Arzneimittel haben wesentlich geringere Verordnungsmengen. Führende Gruppe der klassischen Zytostatika sind die Antimetabolite, was vor allem auf dem hohen Anteil von 5-Fluorouracil und Methotrexat beruht. Als nächste Gruppen folgen monoklonale Antikörper und Proteinkinaseinhibitoren sowie mit deutlichem Abstand Platinverbindungen, Taxane, Vincaalkaloide, Anthrazykline, Alkylanzien und Topoisomerasehemmstoffe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Al-Saleh K, Quinton C, Ellis PM (2012): Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol 19: e9–e15

    Google Scholar 

  • André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116

    Article  PubMed  Google Scholar 

  • Barbui T, Finazzi MC, Finazzi G (2012) Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 26:205–211

    Article  CAS  PubMed  Google Scholar 

  • Barosi G, Zhang MJ, Gale RP (2014): Does ruxolitinib improve survival of persons with MPNassociated myelofibrosis? Should it? Leukemia Jul 16. doi: 10.1038/leu.2014.220. [Epub ahead of print]

    Google Scholar 

  • Beer PA, Erber WN, Campbell PJ, Green AR (2011) How I treat essential thrombocythemia. Blood 117:1472–1482

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Beyer J, Albers P, Altena R, Aparicio J et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24:878–888

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM (2014): Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician. J Clin Oncol. 2014 Jul 21. pii: JCO.2014.55.8262. [Epub ahead of print]

    Google Scholar 

  • Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269

    Article  PubMed  Google Scholar 

  • Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27:1492–1501

    Article  CAS  PubMed  Google Scholar 

  • Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  CAS  PubMed  Google Scholar 

  • Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators (2011): Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377: 914–923

    Google Scholar 

  • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) A randomised comparison of cetuximab monotherapy and cetuximab plus Irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  • Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141

    Article  CAS  PubMed  Google Scholar 

  • De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; Investigators TROPIC (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet 376:1147–1154

    Google Scholar 

  • DeVita VT, Rosenberg SA (2012) Two hundred years of cancer research. N Engl J Med 366:2207–2214

    Article  CAS  PubMed  Google Scholar 

  • Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:4594–4600

    Article  CAS  PubMed  Google Scholar 

  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasinska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705

    Article  CAS  PubMed  Google Scholar 

  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 365:1687–1717

    Article  Google Scholar 

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC (2014) Treatment of HER2-positive breast cancer. Breast 23:128–136

    Article  PubMed  Google Scholar 

  • Food andDAdministration (2011): FDA Commissioner removes breast cancer indication from avastin label. Internet: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm

  • Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  CAS  PubMed  Google Scholar 

  • Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5:292–302

    Article  CAS  PubMed  Google Scholar 

  • Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45

    Article  CAS  PubMed  Google Scholar 

  • Heinemann V, Haas M, Boeck S (2012) Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 38:843–853

    Article  CAS  PubMed  Google Scholar 

  • Hochhaus A, La Rosée P (2013) Maßgeschneiderte Therapie der chronischen myeloischen Leukämie. Internist (Berl) 54:155–163

    Article  CAS  Google Scholar 

  • Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403

    Article  CAS  PubMed  Google Scholar 

  • Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Jabbour E, Kantarjian H (2014) Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89:547–556

    Article  CAS  PubMed  Google Scholar 

  • Jang S, Atkins MB (2013) Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 14:e60–e69

    Article  CAS  PubMed  Google Scholar 

  • Jones RH, Vasey PA (2003) Part I: testicular cancer – management of early disease. Lancet Oncol 4:730–737

    Article  PubMed  Google Scholar 

  • Khasraw M, Bell R, Dang C (2012) Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21:142–149

    Article  PubMed  Google Scholar 

  • Krämer I (2010) Zytostatikaherstellung in der Apotheke. Pharm Unserer Zeit 38:280–287

    Article  Google Scholar 

  • Lecavalier-Barsoum M, Quon H, Abdulkarim B (2014) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 2014 May 15; 5:CD00710–4

    Google Scholar 

  • Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B (2014) International Myeloma Working Group recommendations for global myeloma care. Leukemia 28:981–992

    Article  CAS  PubMed  Google Scholar 

  • Macedo LT, da Costa LAB, Sasse AD (2012) Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12:8–9. doi: 10.1186/1471-2407-12-89

    Article  Google Scholar 

  • Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487

    Article  CAS  PubMed  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  PubMed  Google Scholar 

  • Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I (2012) Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23:307–322

    Article  PubMed  Google Scholar 

  • National Institute for Health and Clinical Excellence (NICE) (2011): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. Internet: guidance. nice.org.uk/TA214/Guidance/pdf/English

    Google Scholar 

  • National Institute of Health and Clinical Excellence (2014): Prostate cancer. Diagnosis and treatment. Issued: January 2014, NICE clinical guideline 175. Internet: http://www.nice.org.uk/guidance/cg175/resources/nice-diagnosing-and-treating-prostate-cancer

  • Navarra P, Preziosi P (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29:249–255

    Article  CAS  PubMed  Google Scholar 

  • O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449

    Article  PubMed  Google Scholar 

  • Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20:3386–3395

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Mina R (2013) Management of older adults with multiple myeloma. Blood Rev 27:133–142

    Article  CAS  PubMed  Google Scholar 

  • Pizzolato JF, Saltz LB (2003) The camptothecins. The Lancet 361:2235–2242

    Article  CAS  Google Scholar 

  • Pox C, Schmiegel W, Reinacher-Schick A (2012): Kolorektales Karzinom – Was gibt's Neues? Dtsch med Wochenschr 137: 2577–2580

    Google Scholar 

  • Rafiyan MR, Jäger E (2013) Medikamentöse Behandlung des metastasierten Nierenzellkarzinoms. Dtsch Med Wochenschr 138:1567–1570

    Article  CAS  PubMed  Google Scholar 

  • Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305:487–494

    Article  CAS  PubMed  Google Scholar 

  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators (2013): Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138–148

    Google Scholar 

  • Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  CAS  PubMed  Google Scholar 

  • Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A (2007) Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007 Oct 17(4):CD00380–5

    Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  CAS  PubMed  Google Scholar 

  • Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  • Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ (2014) Cytotoxic chemotherapy in the contemporary management of metastatic prostate cancer. BJU Int 2014 Jul 21. doi: 10.1111/bju.12867. [Epub ahead of print]

    Google Scholar 

  • Stilgenbauer S, Hallek M (2013) Chronische lymphatische Leukämie. Therapie und genetisches Risikoprofil. Internist (Berl) 54:164–170

    Article  CAS  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  • Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    Article  PubMed  Google Scholar 

  • Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012) Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 2012 Jul 11; 7:CD00894–1

    Google Scholar 

  • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120, Heidelberg

    Prof. Dr. med. W. Jens Zeller

  2. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. W. Jens Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Zeller, W., Schwabe, U. (2014). Onkologika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs- Report 2014. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43487-1_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43487-1_35

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43486-4

  • Online ISBN: 978-3-662-43487-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation